Hints and tips:
...Poland’s health minister Adam Niedzielski said the deal favoured pharmaceutical companies, not EU citizens. He also demanded the confidential contract be published....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The drugmakers Pfizer and Roche said they are piloting use of rFC at some of their facilities....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...This is not just a recent phenomenon: Adam quotes Mark Jones, former director of London’s V&A, on Richard Wallace (1818-90), founder of the Wallace Collection, who “was an outsider, because of being illegitimate...
...“Although [mRNA vaccines] have always shown promise, the infrastructure and experience with large scale manufacturing wasn’t there,” says Adam Barker, an analyst at Shore Capital....
...Kate Adams, Apple’s chief counsel, called the verdict “a huge win”, pointing to the court’s ruling that “Apple is not a monopolist under ‘either federal or state antitrust laws’”....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Both are adenovirus-based vaccines, whereas the BioNTech/Pfizer and Moderna shots use mRNA technology....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...It’s the most accessible of all the vaccines and so will still be used widely if approved,” said Shore Capital’s Adam Barker....
...Among other assignments, he advised Time Warner on its $80bn merger with AT&T, and represented Wyeth during its $68bn sale to Pfizer....
...That’s everything they have always been about,” said Adams Dudley, a professor of medicine at the University of Minnesota ....
...The six chief executives from Merck, Pfizer, AstraZeneca, AbbVie, Sanofi, and Bristol-Myers Squibb, plus an executive president from Johnson & Johnson, will face tough questions on Tuesday on what is fast...
...Disappointed, Pfizer pulled out of neuroscience research last year....
...Adam Cohen, founder of Covenant Review, an independent credit ratings firm, tells the FT: It feels like some kind of venture capital deal with debt....
...Pfizer dropped 1.2 per cent, Merck shed 2 per cent while Eli Lilly and Bristol-Myers Squibb both lost 1 per cent....
...Pfizer, one of the largest US drugmakers, on Tuesday said it was mulling a variety of “strategic alternatives” for its consumer health business, including a spin-off or sale....
...US regulators have granted Pfizer and Eli Lilly an accelerated review for a new type of drug for chronic pain at a time when America is grappling an opioid epidemic....
...“Pfizer needs a deal to deliver consensus earnings per share,” Mr Baum wrote....
...Last year, for example, Halliburton and Baker Hughes scrapped their $28bn marriage while Pfizer abandoned a $160bn takeover of Allergan....
.... ————————————————– News: Amazon agrees to buy Whole Foods for $13.7bn Lex: Grain of truth Video Lex on Whole Foods takeover FT Alphaville: Whole Foods v the activists Markets: Investors gobble up...
...(NYT) News Round-up Private equity funds receive record amounts of capital (FT) China’s hobbled dealmakers yield foreign M&A crown to Japan Inc....
...Pfizer had already split its Innovative Health and Essential Health units internally....
International Edition